AstraZeneca’s blood cancer drug Calquence (acalabrutinib) in combination with obinutuzumab met the primary endpoint at interim analysis in the phase 3 ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia (CLL).
Novartis has announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as to potentially improve long-term outcomes for kidney transplant patients.
Goldfinch Bio has initiated dosing in a Phase 1 clinical trial evaluating GFB-887, its subtype-selective, small molecule TRPC5 inhibitor, as a potential treatment for kidney diseases associated with proteinuria and progressive renal dysfunction including focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD) and diabetic nephropathy (DN).
Roche and AbbVie’s chemotherapy-free combination therapy of Venclexta/Venclyxto (venetoclax) and Gazyva/Gazyvaro (obinutuzumab) succeeded in a phase 3 trial in previously untreated chronic lymphocytic leukaemia (CLL).
CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development in China of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC).
AstraZeneca and Merck presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated (gBRCAm) advanced ovarian cancer, who have received two more prior lines of chemotherapy.
Swiss pharma giant Novartis’ Kisqali (ribociclib) succeeded in a phase 3 trial in combination with endocrine therapy as initial treatment in women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Roche Group member Genentech announced that Xolair (omalizumab) has significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) in two phase III studies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.